versione pdf - Sistema Nazionale Linee Guida

Iperplasia prostatica benignation on Benign Prostatic Hyperplasia. United Kingdom:Health Publications Ltd. 2001.169 Flanigan RC, Reda DJ, Wasson JH, Anderson RJ,Abdellatif M, Bruskewitz RC. 5-year outcome ofsurgical resection and watchful waiting for menwith moderately symptomatic benign prostatichyperplasia: a Department of Veterans Affairscooperative study. J Urol 1998;160:12-6.170 Knutson T, Pettersson S, Dahlstrand C. Pressureflowstudies for patient selection in the treatmentof symptomatic BPH - a one-year follow-up study.Scand J Urol Nephrol 2001;35:470-5.171 Knutson T, Schafer W, Fall M, Pettersson S,Dahlstrand C. Can urodynamic assessment ofoutflow obstruction predict outcome from watchfulwaiting? A four-year follow-up study. ScandJ Urol Nephrol 2001;35:463-9.172 Guideline on the Management of Benign ProstaticHyperplasia. AUA Practice Guidelines 2003:Sito internet AUA: http://www.auanet.org/timssnet/products/guidelines/bph_management.cfm.Accesso 9 giugno 2003.173 De la Rosette JJ, Alivizatos G, Madersbacher S,Perachino M, Thomas D, Desgrandchamps F, etal. for the European Association of Urology. EAUGuidelines on benign prostatic hyperplasia(BPH). Eur Urol 2001;40:256-63.174 Benign Prostatic Hyperplasia: AUA Guidelines2003: Sito internet AUA: http://www.auanet.org/timssnet/products/guidelines/bph_management.cfm175 Kirby RS. A randomized, double-blind crossoverstudy of tamsulosin and controlled-release doxazosinin patients with benign prostatic hyperplasia.BJU Int 2003;91:41-4.176 Kirby RS, Roehrborn C, Boyle P, Bartsch G,Jardin A, Cary MM, Sweeney M, Grossman EB.Efficacy and tolerability of doxazosin and finasteride,alone or in combination, in treatment ofsymptomatic benign prostatic hyperplasia: theProspective European Doxazosin and CombinationTherapy (PREDICT) trial. Urology2003;61:119-26.177 Ahtoy P, Chretien P, Dupain T, Rauch C, RouchouseA, Delfolie A. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment ofbenign prostatic hyperplasia: once daily versus3 times daily dosing in healthy subjects. Int J ClinPharmacol Ther 2002;40:289-94.178 Wilt TJ, MacDonald R, Nelson D. Tamsulosin fortreating lower urinary tract symptoms compatiblewith benign prostatic obstruction: a systematicreview of efficacy and adverse effects. JUrol 2002;167:177-83.179 Roehrborn CG. Efficacy and safety of once-dailyalfuzosin in the treatment of lower urinary tractsymptoms and clinical benign prostatic hyperplasia:a randomized, placebo-controlled trial.Urology 2001;58:953-9.180 Perepanova TS, Kamalov AA, Siniukhin VN,Gorokhnov AV, Khazan PL, Orlova EV. Doxazosin«Cardura» in acute urinary retentioncaused by benign prostatic hyperplasia.Urologiia 2001;3:18-20.181 Baldwin KC, Ginsberg PC, Roehrborn CG, HarkawayRC. Discontinuation of alpha-blockadeafter initial treatment with finasteride and doxazosinin men with lower urinary tract symptomsand clinical evidence of benign prostatic hyperplasia.Urology 2001;58:203-9.182 Van Kerrebroeck PE. The efficacy and safety ofa new once-a-day formulation of an alpha-blocker.Eur Urol 2001;39(suppl 6):19-26.183 Suzuki Y, Katoh T, Isurugi K, Obara W, OmoriS, Goto Y, Fujioka T, Numasato S. The efficacyand safety of terazosin and tamsulosin inpatients with urinary disturbance accompanyingprostatic hypertrophy. Hinyokika Kiyo 2001;47:15-21.184 Kirby RS, Andersen M, Gratzke P, Dahlstrand C,Høye K. A combined analysis of double-blind trialsof the efficacy and tolerability of doxazosingastrointestinaltherapeutic system, doxazosinstandard and placebo in patients with benignprostatic hyperplasia. BJU Int 2001;87:192-200.185 Djavan B, Marberger M. A metanalysis on theefficacy and tolerability of alpha1-adrenoceptorantagonists in patients with lower urinary tractsymptoms suggestive of benign prostatic obstruction.Eur Urol 1999;36:1-13.186 Andersen M, Dahlstrand C, Hoye K. Doubleblindtrial of the efficacy and tolerability of doxazosinin the gastrointestinal therapeutic system,doxazosin standard, and placebo in patientswith benign prostatic hyperplasia. Eur Urol2000;38:400-9.187 Fourcade RO. Efficiency and tolerance of terazosinein ambulatory patients with benign prostatichypertrophy: comparative randomized anddouble-blind trial versus alfuzosin. The MG TerazosineGroup. Prog Urol 2000;10:246-53.188 Tsujii T. Comparison of prazosin, terazosin andtamsulosin in the treatment of symptomaticbenign prostatic hyperplasia: a short-term open,randomized multicenter study. BPH Medical TherapyStudy Group. Benign prostatic hyperplasia.Int J Urol 2000;7:199-205.189 Harada K, Kawaguchi A, Ohmori M, FujimuraA. Antagonistic activity of tamsulosin againsthuman vascular alpha1-adrenergic receptors.Clin Pharmacol Ther 2000;67:405-12.190 Okada H, Kamidono S, Yoshioka T, Okuyama A,Ozono S, Hirao Y, Okajima E, Yamamoto K,Kishimoto T, Park Y, Kurita T. A comparativestudy of terazosin and tamsulosin for symptomaticbenign prostatic hyperplasia in Japanesepatients. BJU Int 2000;85:676-81.191 Van Kerrebroeck P, Jardin A, Laval KU, vanCangh P and the ALFORTI Study Group. Efficacyand safety of a new prolonged release formulationof alfuzosin 10 mg once daily versusalfuzosin 2.5 mg thrice daily and placebo inpatients with symptomatic benign prostatichyperplasia. Eur Urol 2000;37:306-13.192 Curtis SP, Eardley I, Boyce M, Larson P, HaesenR, Gottesdiener K, Gertz BJ. Single dosemethodology to assess the influence of analpha1-adrenoceptor antagonist on uroflow-42Bibliografia essenziale